Day One Biopharmaceuticals (DAWN) News Today

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) shares moved today after a flurry of analyst updates. On the positive side, several firms raised earnings forecasts and price targets amid encouraging trial progress, while others trimmed their outlooks or downgraded the stock, driving it to a new 12-month low.

• Positive Sentiment: Wedbush raised its FY2028 EPS estimate for DAWN to $0.56 (from $0.47) and maintained an “Outperform” rating with a $25.00 price target. What is Wedbush's Estimate for DAWN FY2028 Earnings?
• Positive Sentiment: HC Wainwright boosted its Q3 2025 EPS estimate to ($0.27) from ($0.30), reiterated a “Buy” rating and set a $25.00 target.
• Positive Sentiment: Analysts now see a $29.00 consensus price target on DAWN shares, up from prior levels. Day One Biopharmaceuticals, Inc. Receives $29.00 Consensus PT
• Positive Sentiment: Seeking Alpha upgraded DAWN to “Buy,” noting strong early sales of OJEMDA, an expanding pLGG market share and a deep cash runway ahead of FIREFLY-2 results. Day One Biopharmaceuticals: Bear Case Priced In, But Bull Case Is Not (Rating Upgrade)
• Neutral Sentiment: Wedbush also lifted its Q3 2025 EPS estimate to ($0.28) from ($0.33), keeping its Outperform stance and $25.00 target.
• Negative Sentiment: Needham & Company cut its price objective on DAWN to $16.00 (from $18.00) albeit with a “Buy” rating. Day One Biopharmaceuticals Price Target Lowered to $16.00 at Needham & Company LLC
• Negative Sentiment: H.C. Wainwright trimmed its target on DAWN from $36.00 to $25.00 in a note, despite keeping a Buy rating. Day One price target lowered to $25 from $36 at H.C. Wainwright
• Negative Sentiment: An analyst downgrade pushed DAWN to a new 12-month low, underscoring concerns over pricing and trial timing. Day One Biopharmaceuticals Sets New 12-Month Low on Analyst Downgrade